2008 Design of Medical Devices Conference Abstracts

Nanofiber Covered Stent (NCS) for Vascular Diseases PUBLIC ACCESS

[+] Author and Article Information
Yixiang Dong, Teo Wee Eong, Susan Liao, Casey Chan, S. Ramakrishna

Division of Bioengineering,  National University of Singapore, Singapore

J. Med. Devices 2(2), 027512 (Jun 11, 2008) (1 page) doi:10.1115/1.2936115 History: Published June 11, 2008


Introduction: A covered stent is one whose length and circumference is enclosed with a membrane or fabric like material. Current covered stents have been used in the treatment of failed saphenous vein grafts in coronary bypass and coronary artery perforations. Covered stents have also been proposed in treating brain aneurysm. However, none of these applications showed satisfactory results. The deficiencies of the covered stents are 1) Large wall thickness 2) Rigidity 3) Non-biodegradable polymer with poor endothelialization. Materials and methods: Aligned poly(L-lactide-co-epsilon-caprolactone) [P(LLA-CL)] nanofiber was lon-gitudinally deposited on to a bare metal stent (BMS) by a patent pending electrospinning technique. The NCS were deployed following the instruction to evaluate the expandability. Biocompatibility of the nanofiber was characterized by cell culture, degradation and drug eluting study. Results: The cell viability of Porcine smooth muscle cells (PSMC) on the nanofiber was initially low but caught up after 2weeks. SEM images showed 100% of cell confluence on the nanofiber after 2months. Significant amount of ECM protein was detected on P(LLA-CL) nanofiber (0.07mgcm2 at day 70). Complete degradation of P(LLA-CL) is expected within 6months. Paclitaxel released from drug loaded nanofiber was shown to inhibit PSMC growth but kill Hela cells. NCS was successfully fabricated and deployed without tearing the nanofiber. Conclusions: NCS was successfully fabricated. P(LLA-CL) was chosen for the “cover” with proved superiorities on biocompatibility, cell viability, degradability and drug loading capacity. Future work will be animal study to prove that NCS can reduce in-stent restenosis and promote endothelialization.

Copyright © 2008 by American Society of Mechanical Engineers
This article is only available in the PDF format.





Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging and repositioning the boxes below.

Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In